Clinical Trial Update: Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the combination of interferon alfa-2b (Intron-A) and imiquimod (Aldara) for basal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Aldara (imiquimod)
• Intron A (interferon alfa-2b)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Basal Cell Carcinoma | Phase 4 | Status: COMPLETED